INSIGHTS ON CLINICAL TRIAL DESIGN
-
![GettyImages-1663374966-lab-microscope-mask-research-study]( "5 Questions To Ask Before Selecting A Randomization Partner")
5 Questions To Ask Before Selecting A Randomization PartnerChoose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.
-
![GettyImages-1219551222-Patient-Person-Recruitment-Select]( "Unlocking The Potential of RWD In Clinical Trial Recruitment")
Unlocking The Potential of RWD In Clinical Trial RecruitmentInsights derived from real-world data can be used not only to identify potential patients for participation in clinical research, but also to inform the overall patient engagement and retention strategy of a clinical trial.
-
![GettyImages-1282633951-laptop-man-suit-office-quality-management]( "Endpoint Clinical RTSM: Getting The Job Done")
Endpoint Clinical RTSM: Getting The Job DoneExplore how a Job-to-be-Done (JTBD)-focused RTSM approach reduces delays, optimizes costs, and accelerates trial success through predictive intelligence and streamlined global workflows.
-
![GettyImages-955812666 patient recruitment]( "Redefining Vaccine Trial Recruitment")
Redefining Vaccine Trial RecruitmentModern vaccine trials demand flexible, transparent recruitment workflows. Discover strategies to overcome enrollment delays and build representative, diverse study cohorts.
-
Challenges To Making Go/No-Go Decisions In Clinical Trials7/16/2026
In drug development, a go/no-go decision can be a high-stakes trade-off between speed and certainty. Delve into the real-world operational and strategic hurdles to making those decisions.
-
Analyzing The FDA's Approach To Diversity In Clinical Trials1/31/2025
Learn how utilizing diverse data resources and collaborating with stakeholders enables sponsors to foster a culture of inclusivity, meet regulatory requirements and ultimately advance medical science.
-
Designing More Representative Trials Through Strategic Planning5/28/2025
Strategic planning for representative clinical trials improves outcomes, regulatory alignment, recruitment efficiency, and commercial value by ensuring study populations mirror real-world patients.
-
From Bottlenecks To Breakthroughs: How AI Is Transforming Translation Timelines9/12/2025
Take a deeper look at AI-enabled translations and uncover how they are able to drive a remarkable 43% reduction in overall translation timelines.
-
How AI Is Reshaping Clinical Development And Trial Execution8/6/2026
See how AI, real-world data, and agentic technologies are helping clinical teams improve patient selection, streamline operations, and speed trial outcomes.
CLINICAL TRIAL DESIGN SOLUTIONS
-
![clinical-trials-patients-GettyImages-1629549075]( "Develop Site-Centric Protocols To Optimize Enrollment")
Optimize clinical trial protocols by aligning scientific goals with real-world site operations. Improve enrollment, reduce site burden, and minimize costly amendments through data-driven design.
-
![Diversity-iStock-1313246059]( "Enable Greater Diversity In Clinical Trials")
Discover how to seamlessly integrate a broad range of leading industry solutions to create an innovative, patient-centered approach that caters to specific diversity and clinical trial requirements.
-
![GettyImages-1971327276 doctor patient]( "Balancing The Scales: The Strategic Role Of Stipends In Trial Success")
Traditional clinical trial models can create financial burden by neglecting participant needs – but effective use of stipends can allow participants to fully engage without financial worries.
-
![ai-in-healthcare-GettyImages-1333328712]( "TrialKit AI Timeline Value")
Automate protocol design, database builds, and validation to cut study setup from months to days — enabling faster analytics, earlier insights, and trial simulation.
-
TrialScope Disclose delivers the proven solutions clinical trial sponsors need to centralize, track, register, and comply with clinical trial disclosure processes, mitigating compliance risks while giving them greater control over their own clinical trial disclosure reputation.
